Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.7.3311

Differentially Expressed Proteins in ER+ MCF7 and ER- MDA-MB-231 Human Breast Cancer Cells by RhoGDI-α Silencing and Overexpression  

Hooshmand, Somayeh (Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia)
Ghaderi, Abbas (Cancer Proteomics and Biomarkers Lab, Shiraz Institute for Cancer Research, University of Medical Sciences)
Yusoff, Khatijah (Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia)
Thilakavathy, Karuppiah (Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia)
Rosli, Rozita (Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia)
Mojtahedi, Zahra (Cancer Proteomics and Biomarkers Lab, Shiraz Institute for Cancer Research, University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.7, 2014 , pp. 3311-3317 More about this Journal
Abstract
Background: The consequence of Rho GDP dissociation inhibitor alpha (RhoGDI${\alpha}$) activity on migration and invasion of estrogen receptor positive ($ER^+$) and negative ($ER^-$) breast cancer cells has not been studied using the proteomic approach. Changes in expression of RhoGDI${\alpha}$ and other proteins interacting directly or indirectly with RhoGDI${\alpha}$ in MCF7 and MDA-MB-231, with different metastatic potentials is of particular interest. Materials and Methods: $ER^+$ MCF7 and ER- MDA-MB-231 cell lines were subjected to two-dimensional electrophoresis (2-DE) and spots of interest were identified by matrix-assisted laser desorption/ionization time of- flight/time-of-flight (MALDI-TOF/TOF) mass spectrometry (MS) analysis after downregulation of RhoGDI${\alpha}$ using short interfering RNA (siRNA) and upregulated using GFP-tagged ORF clone of RhoGDI${\alpha}$. Results: The results showed a total of 35 proteins that were either up- or down-regulated in these cells. Here we identifed 9 and 15 proteins differentially expressed with silencing of RhoGDI${\alpha}$ in MCF-7 and the MDA-MB-231 cells, respectively. In addition, 10 proteins were differentially expressed in the upregulation of RhoGDI${\alpha}$ in MCF7, while only one protein was identified in the upregulation of RhoGDI${\alpha}$ in MDA-MB-231. Based on the biological functions of these proteins, the results revealed that proteins involved in cell migration are more strongly altered with RhoGDI-${\alpha}$ activity. Although several of these proteins have been previously indicated in tumorigenesis and invasiveness of breast cancer cells, some ohave not been previously reported to be involved in breast cancer migration. Hence, these proteins may serve as useful candidate biomarkers for tumorigenesis and invasiveness of breast cancer cells. Conclusions: Future studies are needed to determine the mechanisms by which these proteins regulate cell migration. The combination of RhoGDI${\alpha}$ with other potential biomarkers may be a more promising approach in the inhibition of breast cancer cell migration.
Keywords
Proteomics; biomarkers; RhoGDI${\alpha}$; $ER^+$ MCF7; $ERT^-$ MDA-MB-231; breast cancer cells;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Sarvaiya HA, Yoon JH, Lazar IM (2006). Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation. Rapid Commun Mass Spectrom, 20, 3039-55.   DOI   ScienceOn
2 Shida A, Fujioka S, Takahashi N, et al (2013). Reduced expression of Rho GDP dissociation inhibitor 2 mRNA is associated with lymph node metastasis in gastric carcinoma. Oncol Lett, 6, 463-7.   DOI
3 Sofi GN, Sofi JN, Nadeem R, et al (2012). Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev, 13, 5047-52.   과학기술학회마을   DOI   ScienceOn
4 Libertini SJ, Robinson BS, Dhillon NK, et al (2005). Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res, 65, 10700-8.   DOI   ScienceOn
5 Kanaujiya JK, Lochab S, Kapoor I, et al (2013). Proteomic identification of Profilin1 as a corepressor of estrogen receptor alpha in MCF7 breast cancer cells. Proteomics, 13, 2100-12.   DOI   ScienceOn
6 Lai TC, Chou HC, Chen YW, et al (2010). Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel electrophoresis. J Proteome Res, 9, 1302-22.   DOI   ScienceOn
7 Lee S, Terry D, Hurst DR, Welch DR, Sang QX (2011). Protein signatures in human MDA-MB-231 breast cancer cells indicating a more invasive phenotype following knockdown of human endometase/matrilysin-2 by siRNA. J Cancer, 2, 165-76.   DOI
8 Lin M, van Golen KL (2004). Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat, 84, 49-60.   DOI   ScienceOn
9 Mommers EC, van Diest PJ, Leonhart AM, Meijer CJ, Baak JP (1999). Balance of cell proliferation and apoptosis in breast carcinogenesis. Breast Cancer Res Treat, 58, 163-9.   DOI   ScienceOn
10 Nagaraja GM, Othman M, Fox BP, et al (2006). Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene, 25, 2328-38.   DOI   ScienceOn
11 Niemi M, Kervinen K, Kiviniemi H, et al (2000). Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health, 54, 938-9.   DOI
12 Pan J, Sun LC, Tao YF, et al (2011). ATP synthase ecto-alpha-subunit: a novel therapeutic target for breast cancer. J Transl Med, 9, 211.   DOI
13 Grant AG, Flomen RM, Tizard ML, Grant DA (1992). Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer, 50, 740-5.   DOI
14 Ding Z, Joy M, Bhargava R, et al (2013). Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis. Oncogene.???
15 Gast MC, Schellens JH, Beijnen JH (2009). Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat, 116, 17-29.   DOI
16 Graff JR, Konicek BW, Vincent TM, et al (2007). Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest, 117, 2638-48.   DOI   ScienceOn
17 Hoj BR, la Cour JM, Mollerup J, Berchtold MW (2009). ALG-2 knockdown in HeLa cells results in G2/M cell cycle phase accumulation and cell death. Biochem Biophys Res Commun, 378, 145-8.   DOI   ScienceOn
18 Ji Y, Olson J, Zhang J, et al (2008). Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res, 68, 5997-6005.   DOI   ScienceOn
19 Hooshmand S, Ghaderi A, Yusoff K, et al (2013). Downregulation of $RhoGDI\alpha$ increased migration and invasion of ER (+) MCF7 and ER (-) MDA-MB-231 breast cancer cells. Cell Adh Migr, 7, 297-303.   DOI   ScienceOn
20 Hu LD, Zou HF, Zhan SX, Cao KM (2007). Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncol Rep, 17, 1383-9.
21 Bae YH, Ding Z, Zou L, et al (2009). Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol, 219, 354-64.   DOI   ScienceOn
22 Barone I, Brusco L, Gu G, et al (2011). Loss of Rho GDIalpha and resistance to tamoxifen via effects on estrogen receptor alpha. Natl Cancer Inst, 103, 538-52.   DOI   ScienceOn
23 Brenton JD, Carey LA, Ahmed AA, Caldas C (2005). Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Clin Oncol, 23, 7350-60.   DOI   ScienceOn
24 Carragher NO, Fonseca BD, Frame MC (2004). Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. Neoplasia, 6, 53-73.   DOI
25 Chua PJ, Lee EH, Yu Y, et al (2010). Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol, 36, 359-64.
26 Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF (2001). Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res, 61, 6716-22.
27 Strande V, Canelle L, Tastet C, et al (2009). The proteome of the human breast cancer cell line MDA-MB-231: Analysis by LTQ-Orbitrap mass spectrometry. Proteomics Clin, 3, 41-50.   DOI   ScienceOn
28 Zhang SJ, Hu Y, Qian HL, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.. Asian Pac J Cancer Prev, 14, 3937-40.   과학기술학회마을   DOI   ScienceOn
29 Suhane S, Berel D, Ramanujan VK (2011). Biomarker signatures of mitochondrial NDUFS3 in invasive breast carcinoma. Biochem Biophys Res Commun, 412, 590-95.   DOI   ScienceOn
30 Srisomsap C, Sawangareetrakul P, Subhasitanont P, et al (2004). Proteomic analysis of cholangiocarcinoma cell line. Proteomics, 4, 1135-44.   DOI   ScienceOn
31 Stresing V, Baltziskueta E, Rubio N, et al (2013). Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene, 32, 724-35.   DOI   ScienceOn
32 Tari AM, Hung MC, Li K, Lopez-Berestein G (1999). Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene, 18, 1325-32.   DOI
33 Undyala VV, Dembo M, Cembrola K, et al (2008). The calpain small subunit regulates cell-substrate mechanical interactions during fibroblast migration. J Cell Sci, 121, 3581-8.   DOI   ScienceOn
34 Rho SB, Song YJ, Lim MC, et al (2012). Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell Signal, 24, 131-9.   DOI   ScienceOn
35 Wilkins MR, Pasquali C, Appel RD, et al (1996). From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology, 14, 61-5.   DOI   ScienceOn
36 Yamada Y, Arao T, Gotoda T, et al (2008). Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci, 99, 2193-9.   DOI   ScienceOn
37 Yan Y, Mahotka C, Heikaus S, et al (2004). Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br J Cancer, 91, 1349-57.   DOI   ScienceOn
38 Pluta P, Cebula-Obrzut B, Ehemann V, et al (2011). Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma, 58, 430-5.   DOI
39 Pola C (2012). Cancer: Antitumor duality of ApoE. Nature Medicine, 18, 1752.
40 Reis-Filho JS, Lakhani SR (2003). The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res, 5, 313-9.   DOI   ScienceOn
41 Ryu J, Song J, Heo J, et al (2011). Cross-regulation between protein L-isoaspartyl O-methyltransferase and ERK in epithelial mesenchymal transition of MDA-MB-231 cells. Acta Pharmacol Sin, 32, 1165-72.   DOI   ScienceOn
42 Salicioni AM, Xi M, Vanderveer LA, et al (2000). Identification and structural analysis of human RBM8A and RBM8B: two highly conserved RNA-binding motif proteins that interact with OVCA1, a candidate tumor suppressor. Genomics, 69, 54-62.   DOI   ScienceOn